RankAlpha logo
Back to Rankings

BEAM

Beam TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
The post-Q2 operating update was constructive: Beam advanced BEAM-302 into a pivotal cohort, retained a mid-2029 cash runway, completed key BEACON dosing, and advanced BEAM-304 toward the clinic [#SEC-8K-2026-08-04]. These milestones support a cautiously positive pipeline thesis.
Posture
Constructive
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bearish as of 2026-09-10.
What can break
BEAM-302, BEAM-301, and BEAM-304 remain clinical-stage programs exposed to safety, efficacy, enrollment, and timing setbacks.
Momentum
19
Value
41
Sentiment
95
Setup hits (3d)
1 · Net Bearish
AI TargetsBase $31.00 · Bull $44.00 · Bear $18.00Analysis 2026-08-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-14 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-09-10

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions

Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bearish
Target $51.07
Why
Momentum19 · Δ7d -28.8
Value41 · Δ7d -0.0
Sentiment95 · Δ7d +24.1
So what
Strength-led posture (Net Bearish). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • 1 setup hits (3d) with net bearish as of 2026-09-10.
  • • Sentiment remains the lead driver in the composite, 7D delta +24.1.

Contradictions & invalidation

  • • BEAM-302, BEAM-301, and BEAM-304 remain clinical-stage programs exposed to safety, efficacy, enrollment, and timing setbacks.
  • • Cash runway into mid-2029 reduces near-term financing pressure but does not remove ongoing cash-burn and future-capital risk.
  • • The valuation remains dependent on clinical efficacy, safety, enrollment, regulatory execution, and eventual commercialization.

Catalyst clock

2026-08-04

Q2 execution and extended cash runway

Lead driver: Sentiment · See AI snapshot
Momentum
19
9% active weight
Current posture
7d trendSoftening
Δ7d
-28.8
Δ21d
+2.1
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
95
62% active weight
Current posture
7d trendImproving
Δ7d
+24.1
Δ21d
+19.0
Why this grade

Composite grade A. Momentum 19.2 / Value 41.2 / Sentiment 95.2

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-14. Scenario method

B+
Bull case
25%
Probability
Target price
$44.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$31.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$2.8B
Beta
2.12
Shares Out
103.29M
P/E (TTM) · Derived
-33.5
P/S (TTM)
48.90
P/FCF (TTM) · Derived
-7.54
Rev YoY
-94.2%
EPS YoY
+17.4%
Gross Margin
+85.7%
Op Margin
-242.3%
Net Debt
-$1.09B
Current Ratio
14.57
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data